QRxPharma Pty Ltd.
This article was originally published in Start Up
Executive Summary
QRx's lead (Phase II) candidate is a morphine/oxycodone combination that takes advantage of the synergistic effect of those two opioids when combined to produce a more potent painkiller, with fewer side effects, than morphine administered alone. The company is also developing an extended-release version of the drug and has a platform for discovering venom-based therapeutics.
You may also be interested in...
Pain Therapeutics: A Market Rich in Unmet Medical Need and Competition
Start-ups venturing into the pain management arena will find them selves in a therapeutic category rich in both unmet medical need and competition. To compete, a number of newer companies are pursuing business models that balance the risks inherent in developing novel painkillers with more reliable, predictable routes to commercialization--such as creating next-generation versions of off-patent drugs and inlicensed technology, as well as establishing IP around already-elucidated targets.
FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development
US FDA Commissioner Califf praises both Project Pragmatica and the ‘very powerful’ partnership between OCE Director Rick Pazdur and National Cancer Institute Director Monica Bertagnolli.
California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target
Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.